Incyte’s science-first approach and heritage in immunology has formed the foundation of our company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need.

Our research and development efforts in dermatology are initially focused on leveraging our knowledge of the JAK-STAT pathway. We are exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa.

Research has shown that the JAK-STAT pathway mediates the cellular effects of cytokines involved in the pathogenesis of many immune-mediated dermatologic conditions. We strive to identify and develop therapies to modulate immune pathways driving uncontrolled inflammation to help restore normal immune function and bring the body closer to homeostasis.

Learn more at https://incyte.com/what-we-do/dermatology

At UCB, everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” We have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe diseases of the immune system and the central nervous system. We do that by connecting with patients and their families around the world living with the physical and social burdens of severe disease. Those connections offer new perspectives, drive innovation, and offer the hope of a new generation of therapies that are helping to transform lives.

With a team of more than 7,500 employees and operations in 40 countries, we are a global biopharmaceutical company investing nearly 25% of revenue in cutting-edge scientific research to meet unmet patient needs. The company is based in Brussels, Belgium, with U.S. headquarters located in Atlanta, Georgia.

Learn more at https://www.ucb.com/